Introduction
============

Primary open angle glaucoma (POAG) is a complex heterogeneous disease and by the year 2020 is predicted to affect more than 50 million people worldwide \[[@r1]\]. Excavation of the optic disc with corresponding loss of visual field is the principal hallmark of POAG. Since its implication in the pathogenesis of POAG in 1997, numerous mutations in the *myocilin* (*MYOC*) gene have been identified and their specific phenotypes characterized \[[@r2],[@r3]\]. The work recently performed by Shepard and colleagues has revealed that disease severity in *MYOC*-related POAG is influenced by exposure of a cryptic signaling site \[[@r4]\].

Worldwide, the Thr377Met *MYOC* mutation is one of the most commonly identified POAG-causing mutations and it has been previously identified in populations from five different continents. This specific mutation has been identified in four Australian-based families, two families residing in the United States of America, and one each from Greece, the former Yugoslavian Republic of Macedonia (FYROM), India, Finland, and Morocco \[[@r5]-[@r12]\]. The Thr377Met *MYOC* mutation is located within the COOH-terminal coding region and renders the protein insoluble \[[@r13]\]. Although this highly penetrant mutation appears to be sufficient to cause disease, evidence supporting gene-gene interaction in adult onset glaucoma has been described in a family harboring this variant \[[@r11]\]. Members of a Greek family who carried both the Thr377Met *MYOC* mutation and a haplotype associated with the GLC1C locus displayed greater disease severity than did those family members with only one disease variant \[[@r11]\].

In general, the Thr377Met mutation confers disease of intermediate severity, with patients typically being diagnosed in their fourth decade (weighted mean of age at diagnosis across described pedigrees=41.4 years). This is younger than the age at which patients with the Gln368Stop mutation are usually diagnosed, yet somewhat older than those carrying other *MYOC* mutations such as Pro370Leu, which is generally diagnosed around 15 years of age \[[@r5]-[@r12]\]. Following a similar pattern, patients with the Thr377Met mutation tend to have a maximum recorded intraocular pressure around 30 mmHg, lower than that described for mutations causing juvenile onset glaucoma (such as Pro370Leu), though generally higher than for the Gln368Stop mutation \[[@r7]\].

Inherited diseases with a relatively late onset may be more likely to have a common disease founder than those which manifest at a younger age. Evidence for a founding effect has previously been reported for the common Gln368Stop *MYOC* mutation; however, others, such as the Gly367Arg mutation, have arisen independently several times \[[@r14]-[@r16]\]. Small, local founder effects have also been identified for other less common mutations \[[@r9],[@r14],[@r17]-[@r19]\]. It is unclear whether a POAG variant causing intermediate disease severity would disseminate worldwide. Herein, we identified the haplotypes associated with the Thr377Met MYOC mutation to evaluate a possible founder effect in POAG families from various different ethnic backgrounds. To assess the degree of linkage disequilibrium across *MYOC* in the general population we also investigated data generated from the HapMap consortium.

Methods
=======

Nine Thr377Met *MYOC* glaucoma pedigrees from the United States of America, Greece, Finland, India, and Australia were recruited. The four Australian families had emigrated from Great Britain, Greece, and Macedonia. Both families from the United States of America were of Greek ethnicity ([Table 1](#t1){ref-type="table"}). The Indian proband lived in a Sino-Tibetan linguistic region. This study adhered to the Declaration of Helsinki and ethical approval had previously been obtained by each research group\'s respective local Institutional Review Board, as previously reported \[[@r5]-[@r12]\].

###### Summary of phenotypic features of glaucomatous individuals carrying the Thr377Met *MYOC* mutation.

  ------------------------ ------------------------------------------------ ------------------------------------------ ---------------------------------------- ------------------------------------------- --------------------------------------
  **Family designation**   **Country of residence (Ancestral Ethnicity)**   **n ofPOAG orOHT individuals described**   **Mean ± SE age at diagnosis (years)**   **Mean ± SE maximum recorded IOP (mmHg)**   **Previous Description of Pedigree**
  Vicl                     Australia (British)                              19                                         39 ±2.5                                  29.9= 1.8                                   \[[@r5]\]
  Vicll8                   Australia (Greek)                                1                                          57                                       60                                          \[[@r5]\]
  Vic119                   Australia (Greek)                                2                                          42 ±10                                   38±8                                        \[[@r5]\]
  Vic120                   Australia (Macedonian)                           1                                          47                                       30                                          \[[@r5]\]
  Epl                      Greece (Greek)                                   9                                          51.3 ±4.9                                32 ±3.8                                     \[[@r11]\]
  UMJG7                    USA (Greek)                                      3                                          38 ± 1.7                                 44 ±1.7                                     \[[@r7]\]
  HMS7                     USA (Greek)                                      1                                          42                                       24                                          \[[@r6]\]
  Finl                     Finland (Finnish)                                9                                          34.3 ± 8.8                               33.2 ±5.5                                   \[[@r10]\]
  Indl                     India (Sino-Tibetan)                             1                                          52                                       44                                          \[[@r8]\]
  \-                       Morocco (Berber)                                 1                                          36                                       70                                          191
  ------------------------ ------------------------------------------------ ------------------------------------------ ---------------------------------------- ------------------------------------------- --------------------------------------

In the table, abbreviations are: n, number; SE, standard error; POAG, primary open angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; USA, United States of America.

Six microsatellite markers (D1S2851, MY3, My5, D1S1619, D1S2790, and D1S242) and four single nucleotide polymorphisms (rs3768570, rs235858, rs171000, and rs235873) located within a four Mb region surrounding the *MYOC* gene were genotyped in available subjects from each pedigree. Primer sequence and PCR conditions are available upon request. Haplotypes in each family were constructed by visual inspection of the genotype data, with no recombinations assumed between the markers. Genomic DNA was available from only one individual from the Indian cohort.

To estimate the probability of finding non-coincidental haplotypes segregating with the founded Thr377Met *MYOC* mutation, we determined the frequencies of the associated neighboring alleles in a sample of POAG patients originating from the same ethnic background. Thirty-three genealogically unrelated POAG patients of Greek ethnicity who, on direct sequencing, were found not to have the Thr377Met *MYOC* mutation, were recruited. The frequencies of the founded haplotype between the Greek Thr377Met *MYOC* mutation carrying patients and the Greek non-*MYOC* POAG patients was compared using Fisher\'s exact test (Intercooled Stata 7.0 for Windows; Stata Corporation, College Station, TX).

Allele frequencies and linkage disequilibrium across the chromosome region 1q24 was assessed using [HapMap](http://www.hapmap.org) data \[[@r20]\]. Phase I and II data were accessed from public release 21. This data release contains all processed data from the project including genotypes from the Affymetric 500 k genotyping array. HapMap comprises data of genotyped individuals from the Centre d\'Etude du Polymorphisme Humain collection in Utah; the Yoruba in Ibadan, Nigeria; the Han Chinese in Beijing, China; and the Japanese in Tokyo, Japan \[[@r20]\]. Haplotype blocks were reviewed using Haploview 3.32 \[[@r21]\] and defined as having an upper confidence interval maximum for strong recombination of 0.9 \[[@r22]\]. Markers with a minor allele frequency below 0.05 were excluded \[[@r22]\].

Results
=======

Genotyping of the microsatellite markers revealed a shared haplotype in mutation carriers across six families from Greece, the United States of America, and Australia ([Table 2](#t2){ref-type="table"}). All of these families were known to be of Greek or Macedonian ethnicity and recombination was found to have occurred in a region telomeric to *MYOC* between D1S1619 and D1S2790.

###### Ancestral disease haplotype shared by individuals carrying the Thr377Met *MYOC* mutation from different ethnic backgrounds.

  -------------------------------------------------- -------------------------------- ----------- -------------------------- ------------ -------------
  **Marker**                                         **Chromosome 1 location (Mb)**   **Greek**   **Australian (British)**   **Indian**   **Finnish**
  D1S2851                                            167.048                          187         187                        177 181      187
  rs3768570                                          167.89                           \-          G                          G/A          A
  rs235858                                           168.328                          \-          G                          G/A          A
  rs171000                                           168.33                           \-          G                          G/T          1
  MY3                                                168.336                          176         174                        174/ 178     178
  rs235873                                           168.344                          \-          G                          G/A          A
  My5 (NGA17)                                        168.454                          239         239                        239          243
  D1S1619                                            168.469                          198         192                        198/200      192
  D1S2790                                            169.756                          \-          243                        243 / 249    249
  D1S242                                             171.104                          \-          215                        221          217
  Number of contributing pedigrees:                  6                                1           1                          1            
  Number of mutation carrying subjects haplotyped:   26                               12          1                          4            
  -------------------------------------------------- -------------------------------- ----------- -------------------------- ------------ -------------

To investigate whether the haplotype observed in the Greek/FYROM Thr377Met *MYOC* families was inherited only by chance we genotyped a small cohort of POAG patients of Greek ethnicity who were known not to have the Thr377Met *MYOC* mutation. Although the precise phase could not be fully determined because of the limited availability of other family members, one Greek patient with POAG was found to have markers (between My3 and D1S1619) in common with the founded Greek Thr377Met *MYOC* mutation. However, even with the conservative assumption that this patient did have the founded MYOC haplotype, our data supports the rejection of the hypothesis that the Greek Thr377Met haplotype merely represents frequent alleles (p\<0.0001).

The families from Finland and Great Britain were found to have differing haplotypes from each other and from those which originated from Greece or Macedonia. This suggests that the Thr377Met *MYOC* mutation has arisen at least three times worldwide. The Indian proband was found to have some markers in common both with the Finnish pedigree and the family which originated from Great Britain. However, given that only one case from this family could be ascertained, the haplotype segregating with the Thr377Met *MYOC* mutation could not be fully determined.

Reviewing the data generated by the HapMap consortium revealed that linkage disequilibrium across *MYOC*, particularly in the Utah residents, was not strong ([Figure 1](#f1){ref-type="fig"}). Larger linkage disequilibrium blocks over the genes neighboring *MYOC* (*HbxAg transactivated protein 2* and *vesicle-associated membrane protein 4*) were identified. In each population linkage disequilibrium was generally stronger across exons 2 and 3 compared to the 5\' region of the *MYOC* gene.

![Haplotype blocks of the 320 kbp region containing the *myocilin* (*MYOC*) gene, in subjects from the Centre d\'Etude du Polymorphisme Humain collection in Utah. The plotted D\' statistic is orientated to the *MYOC* ideogram position and the strength of linkage disequilibrium is displayed in increasing shades of red for higher values. The relative gene locations are indicated by yellow bars.](mv-v13-487-f1){#f1}

Discussion
==========

Pre-symptomatic screening for glaucoma is an attractive prospect and although it may be currently uneconomical to introduce *MYOC* gene screening in a population-wide approach, targeted screening is warranted in selected populations. Our results imply that the Thr377Met *MYOC* mutation should be considered in glaucoma patients of Greek descent in particular.

A common haplotype was identified with the Thr377Met *MYOC* in six of the nine genealogically independent pedigrees studied. The northern boundary of Epirus, Greece, where the *Ep1* family in this report lives, forms the southern edge of the FYROM. Given this geographical proximity, we surmised that the Australian families from Greece and the FYROM have a common founder. However, the British, Finnish, and Indian families have a distinct haplotype from the Greek one, suggesting that the Thr377Met mutation has occurred de novo more than once ([Figure 2](#f2){ref-type="fig"}). Unfortunately refinement of the haplotype associated with this mutation in the Indian case was limited by the lack of genetically informative relatives. Nonetheless, we hypothesize that a Finnish-Indian connection would be at least 1,500 years old, from when the Finno-Ugric (Huns) people migrated from Central Asia. To investigate this inferred dissemination further it would be imperative to collect additional samples from the Indian Thr377Met *MYOC* family, as well as other unrelated Indian POAG cases. A limitation of our work is that the location of the centromeric and telomeric recombination in each pedigree was not identified. Such information would allow for the identification of the minimal common genomic distance between mutation carriers and, in turn, provide an estimation of the age at which the Thr377Met mutation occurred, yet is beyond the scope of this work \[[@r23],[@r24]\].

![The worldwide spread of the Thr377Met *MYOC* mutation. Stars indicate location of known origin, solid arrows indicate known migrations, and the dashed arrow indicates an inferred migration.](mv-v13-487-f2){#f2}

The population spread of human disease is significantly influenced by relative selection pressures and the existence of founder effects raises questions about whether such pressures are playing a role in *MYOC* allele frequencies. Our results, coupled with the late age at diagnosis (with the weighted mean across published pedigrees being 41.4 years), suggest that the Thr377Met *MYOC* mutation alone may not be significantly detrimental to reproduction. Although it is possible to arrive at a founder effect through non-selective processes such as genetic drift, it is plausible that this glaucoma-causing mutation may act as a protective factor against a separate ailment, thereby positively affecting biological fitness. Further insights may come from studies of Thr377Met allele frequencies in the Greek glaucoma populations. Evidence for genetic founder effects in this prevalent age-related, yet heterogeneous, disease has important implications for future gene identification strategies.

The haplotype structure across the comparatively small region surrounding *MYOC*, in conjunction with relatively small proportion of disease accounted for by mutations in *MYOC*, suggests that a high density SNP platform would be required for it to have been identified using a genome-wide association case-control approach. Nevertheless, genes with a different allelic architecture could be identified using such technology and, interestingly, a common disease haplotype has recently been associated with the common Y402H variant of *Complement Factor H* implicated in age-related macular degeneration \[[@r25]\]. Although confined conclusions based on the HapMap data must be approached with caution and the populations from which the data were generated should not be over-generalized, we found that linkage disequilibrium was marginally stronger across the regions with greater cross-species homology (particularly exon 3). Interestingly this supports other findings that on a genome-wide level sequence conservation appears not to be an important predictor of linkage disequilibrium \[[@r26]\].

In summary, the Thr377Met *MYOC* mutation has arisen at least three times in independent populations. Interestingly however, HapMap data suggest that linkage disequilibrium across *MYOC* is not strong. Evidence for genetic founder effects in this prevalent age-related, yet heterogeneous disease has important implications for future gene identification strategies.
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